Netherlands and Ireland became the latest countries to suspend use of the Oxford-AstraZeneca coronavirus vaccine over concerns about possible side effects.
The Dutch government said the move, which will last until at least 29 March, was a precaution.
The Republic of Ireland made a similar decision over reports of blood clotting events in adults in Norway.
But the World Health Organisation says there is no link between the jab and an increased risk of developing a clot.
The European Medicines Agency, who carrying out a review into incidents of blood clots said the vaccine’s benefits continue to outweigh its risks.
Denmark, Norway, Bulgaria, Iceland and Thailand have already halted their use of the AstraZeneca vaccine.
In a statement, AstraZeneca said there was no evidence of an increased risk of clotting due to the vaccine.
It said that across the EU and United Kingdom there had been 15 events of deep-vein thrombosis (DVT) and 22 events of pulmonary embolism reported among those vaccinated.
“Around 17 million people in the EU and UK have now received our vaccine, and the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population,” said Ann Taylor, the firm’s chief medical officer.
“The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety.”